Lipid disorders in patients with HIV-induced diseases;Les désordres lipidiques des patients atteints d'affections causées par le VIH

Presse Medicale

Volumn 34, Issue 15, 2005, Pages 1087-1094

  Chanu, Bernard ^a   Valensi, P ^a  

^a HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTILIPEMIC AGENT; ATAZANAVIR; CRIVIXAN; CYTOKINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROGENESIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; INSULIN RESISTANCE; LIPID METABOLISM; LIPODYSTROPHY; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 24944521077     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84124-7     Document Type: Review

References (49)

1. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
2. Penzak SR, Chuck SK. Management of protease inhibitor-associated hyperlipidemia. Am J Cardiovasc Drugs 2002; 2: 91-106.
3. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovast Dis 2003; 45: 293-304.
4. Verges B, Petit JM. Anomalies des lipides sériques au cours du traitement par les antiprotéases. Presse Med 2001; 30: 911-14.
5. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001; 51: 151-77.
6. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859-63.
7. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100: 700-5.
8. Martinez E, Domingo P, Galindo MJ, Milinkovic A, Arroyo JA, Baldovi F et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004; 38: 1017-23.
9. Malavazi I, Abrao EP, Mikawa AY, Landgraf VO, da Costa PI. Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status. Clin Chem Lab Med 2004; 42: 525-32.
10. Lee GA, Seneviratne T, Noor MA, Lo JC, Scharz JM, Aweeka FT et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004; 18: 641-9.
11. Allan DA, Behrman AJ. Lipid abnormalities in a Healthcare worker receiving HIV prophylaxis. Int J STD AIDS 2001; 12: 532-4.
12. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 10-14.
13. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A et al.; DAD Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-74.
14. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Highlights of the 11th conference on retroviruses and opportunistic infections, february 8-11, 2004, San Francisco, California, USA. Top HIV Med 2004;12:31-45.
15. Negredo E, Ribalta J, Ferre R, Salazar J, Rey-Joly C, Sirera G et al. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004; 18: 819-21.
16. Vigouroux C, Magré J, Desbois-Mouthon C, Lascols O, Cherqui G, Caron M, Capeau J. Syndromes d'insulinorésistance majeure: clinique et physiopathologie. Sang Thromb Vaiss 2001; 13: 21-9.
17. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1467-75.
18. Capeau J, Bastard JP, Caron M, Vigouroux C, Maachi M, Cervera P et al. VIH, lipodystrophies et troubles metaboliques. Sang Thromb Vaiss 2003; 15: 487-98.
19. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9.
20. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25: 1253-4.
21. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
22. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8.
23. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352: 1881-3.
24. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
25. Miller J, Carr A, Emery S, Law M, Mallal S, Baker D et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4: 293-301.
26. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-9.
27. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W, Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 1999; 25: 383-92.
28. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-88.
29. Murata H, Hruz PW, Mueckler M. Investigating the cellular targets of VIH protease inhibitors: implications for metabolic disorders and improvements in drug therapy. Curr Drug Targets Infect Disord 2002; 2: 1-8.
30. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL. VIH protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7: 1327-31.
31. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. VIH protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276: 37514-9.
32. Bonnet E, Ruidavets JB, Tuech J, Ferrieres J, Collet X, Fauvel J et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in VIH-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001; 86: 296-302.
33. Van der Valk M, Bisschop PH, Romijn JA. Lipodystrophy in VIH-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001; 15: 2093-100.
34. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-6.
35. Rickerts V, Brodt H-R, Staszewski S, Stille W. Incidence of myocardial infarction in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5: 329-33.
36. Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of treatment with protease inhibitor on myocardial infarction in HIV-infected men. Abstract 657. 8th Conference on Retrovirus and Opportunistic infections. Feb 2001.
37. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000; 32:111-23.
38. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG et al. Management of metabolic complications associated with antiretroviral therapy for VIH-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-75.
39. de Luis Roman DA, Bachiller P, Izaola O, Romero E, Martin J, Arranz M et al. Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial. Eur J Clin Nutr 2001; 55: 1048-52.
40. Dube MP, Sprecher D, Henry WK, Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations. Adult Clin Infect Dis 2000; 31: 1216-24.
41. Geletko SM, ZuWallack AR. Treatment of hyperlipidemia in HIV-infected patients. Am J Health Syst Pharm 2001; 58: 607-14.
42. Farnier M. Statines et prévention cardio-vasculaire: les enseignements des essais cliniques. Mt endocrinologie 2002; 4: 239-46.
43. Clotet B, Negredo E. HIV protease inhibitors and dyslipidemia. AIDS Rev 2003; 5:19-24.
44. Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002; 1: 5-17.
45. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000; 20: 1066-71.
46. Caramelli B, de Bernoche CY, Sartori AM, Sposito AC, Santos RD, Monachini MC et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis 2001; 5: 332-8.
47. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004; 172: 273-9.
48. Bonnet F, Balestre E, Thiebaut R, Mercie P, Dupon M, Morlat P et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med 2004; 5: 133-9.
49. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002; 30: 26-31.